6B4W

TTK in Complex with Inhibitor


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.9 Å
  • R-Value Free: 0.253 
  • R-Value Work: 0.191 

wwPDB Validation 3D Report Full Report


This is version 2.0 of the entry. See complete history

Literature

The Discovery of a Dual TTK Protein Kinase/CDC2-Like Kinase (CLK2) Inhibitor for the Treatment of Triple Negative Breast Cancer Initiated from a Phenotypic Screen.

Riggs, J.R.Nagy, M.Elsner, J.Erdman, P.Cashion, D.Robinson, D.Harris, R.Huang, D.Tehrani, L.Deyanat-Yazdi, G.Narla, R.K.Peng, X.Tran, T.Barnes, L.Miller, T.Katz, J.Tang, Y.Chen, M.Moghaddam, M.F.Bahmanyar, S.Pagarigan, B.Delker, S.LeBrun, L.Chamberlain, P.P.Calabrese, A.Canan, S.S.Leftheris, K.Zhu, D.Boylan, J.F.

(2017) J. Med. Chem. 60: 8989-9002

  • DOI: 10.1021/acs.jmedchem.7b01223

  • PubMed Abstract: 
  • Triple negative breast cancer (TNBC) remains a serious unmet medical need with discouragingly high relapse rates. We report here the synthesis and structure-activity relationship (SAR) of a novel series of 2,4,5-trisubstituted-7H-pyrrolo[2,3-d]pyrimi ...

    Triple negative breast cancer (TNBC) remains a serious unmet medical need with discouragingly high relapse rates. We report here the synthesis and structure-activity relationship (SAR) of a novel series of 2,4,5-trisubstituted-7H-pyrrolo[2,3-d]pyrimidines with potent activity against TNBC tumor cell lines. These compounds were discovered from a TNBC phenotypic screen and possess a unique dual inhibition profile targeting TTK (mitotic exit) and CLK2 (mRNA splicing). Design and optimization, driven with a TNBC tumor cell assay, identified potent and selective compounds with favorable in vitro and in vivo activity profiles and good iv PK properties. This cell-based driven SAR produced compounds with strong single agent in vivo efficacy in multiple TNBC xenograft models without significant body weight loss. These data supported the nomination of CC-671 into IND-enabling studies as a single agent TNBC therapy.


    Organizational Affiliation

    Celgene Corporation , 10300 Campus Pointe Drive, Suite 100, San Diego, California 92121, United States.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Dual specificity protein kinase TTK
A
303Homo sapiensGene Names: TTK (MPS1, MPS1L1)
EC: 2.7.12.1
Find proteins for P33981 (Homo sapiens)
Go to Gene View: TTK
Go to UniProtKB:  P33981
Small Molecules
Ligands 2 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
CQ7
Query on CQ7

Download SDF File 
Download CCD File 
A
4-{[4-(cyclopentyloxy)-5-(2-methyl-1,3-benzoxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl]amino}-3-methoxy-N-methylbenzamide
C28 H28 N6 O4
CWJLAVRXVFHDSJ-UHFFFAOYSA-N
 Ligand Interaction
CAC
Query on CAC

Download SDF File 
Download CCD File 
A
CACODYLATE ION
dimethylarsinate
C2 H6 As O2
OGGXGZAMXPVRFZ-UHFFFAOYSA-M
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.9 Å
  • R-Value Free: 0.253 
  • R-Value Work: 0.191 
  • Space Group: I 2 2 2
Unit Cell:
Length (Å)Angle (°)
a = 71.351α = 90.00
b = 109.581β = 90.00
c = 114.401γ = 90.00
Software Package:
Software NamePurpose
HKL-2000data reduction
PHASERphasing
REFMACrefinement
HKL-2000data scaling

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

Revision History 

  • Version 1.0: 2017-10-25
    Type: Initial release
  • Version 2.0: 2017-11-22
    Type: Database references, Polymer sequence